NRG1 Fusion Pancreatic Cancer begins when cancer has contact with a gene called Neuregulin 1. With the fusion of cancer cells with the type of protein, known as Neuregulin 1 or NRG1, it is possible that the disease can reach the stage where it is diagnosed.
In the diagnosis of NRG1 Fusion Pancreatic Cancer patient, it is important to first treat traumas in the gene of the patient and begin early treatment.
What is NRG1 Fusion Pancreatic Cancer?
The pancreas is one of the most important organs of the body. The pancreas, which is around 15 cm. as a structure is located behind the abdomen and next to the duodenum, liver, and large intestine.
Cancerous cells that have started in any part of the body and reached the pancreas or cancer cells that reproduce directly in the pancreas result in a diagnosis of pancreatic cancer.
NRG1 is a gene in the epidermal growth factor group in humans. There are four different proteins that act on the EGFR receptor family and NRG1 is one of these quadruple proteins.
Pancreatic Cancer is one of the types of cancer that is relatively difficult to diagnose. Neuregulin 1 Fusion Pancreatic Cancer, which is the fusion of the cancerous cell with the NRG 1 gene, is also in the category of diseases that are difficult to diagnose in this sense.
What are the Symptoms of NRG1 Fusion Pancreatic Cancer?
In NRG1 Fusion Pancreatic Cancer, the symptoms found in other pancreatic cancer patients are as follows:
- Loss of appetite
- Weight loss depending on time
- Pain in the abdomen
- Weakness and nausea
- Fatigue and diarrhea
- Discoloration in feces
Methods of Treatment of the Disease
It is possible to remove and treat cancerous cells that have penetrated the NRG1 gene with pancreatic cancer. In addition to traditional treatment, clinical treatment methods are applied for the treatment, which have 4 different stages from the initial and early diagnosis period.
Many of the methods with effective results in various types of cancer disease arise from clinical treatment studies. As with other types of cancer, NRG1 Fusion Pancreatic Cancer clinical trials may be preferred where traditional methods are lacking. However, since these treatments are still in the FDA approval process; you should consult your doctor if you are eligible to participate in such a program.
Massive Bio helps to determine the most appropriate treatment for the patient with its database of all clinical trials and effective screening system. Massive Bio uses an AI-based precision oncology clinical trial matching tool supported by the Virtual Tumor Board (VTB) program. The SYNERGY-AI recording system uses artificial intelligence to speed up clinical trial pairings. Genomics is the first of its kind as a system that combines biological and multivariate analyses.